% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zimmermann:307460,
      author       = {N. Zimmermann and J. Kött and T. Zell and A. Z. Abedini
                      and C. L. Blomen and S. Belz and B. Deitert and I. Heidrich
                      and G. Geidel and A. Rünger and D. J. Smit and M.
                      Weichenthal and S. Ugurel and U. Leiter and C. Berking and
                      R. Gutzmer and D. Schadendorf$^*$ and I. von Wasielewski and
                      P. Mohr and F. Meier and R. Herbst and J. Utikal$^*$ and P.
                      Terheyden and S. Haferkamp and C. Pföhler and M. Kaatz and
                      F. Ziller and J. Ulrich and F. Meiss and A. T. Bauer and S.
                      W. Schneider and C. Gebhardt},
      title        = {{E}nhanced overall and progression-free survival in
                      advanced melanoma patients undergoing targeted therapy
                      alongside antithrombotic treatment - {I}nsights from a
                      multicenter study involving 1296 patients from the
                      prospective skin cancer registry {ADOR}eg.},
      journal      = {European journal of cancer},
      volume       = {234},
      issn         = {0959-8049},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-03059},
      pages        = {116195},
      year         = {2026},
      note         = {2025 Dec 19:234:116195 / Available online 19 December 2025},
      abstract     = {Targeted therapies (TT) improve outcomes in BRAF-mutant
                      melanoma. Pre-clinical data suggest that anticoagulation
                      (AC) and platelet aggregation inhibition (PAI) may have
                      antitumoral effects. We evaluated the impact of concomitant
                      AC or PAI on outcomes in patients receiving TT.We analyzed
                      1296 patients with unresectable stage III-IV BRAF-mutant
                      melanoma treated with BRAF plus MEK inhibitors (2016-2024)
                      in the prospective multicenter ADOReg registry. Patients
                      were categorized as receiving no antithrombotic therapy
                      (ATT; n = 1125), PAI (n = 73; acetylsalicylic acid or
                      clopidogrel), or AC (n = 98; direct oral anticoagulants,
                      low-molecular-weight heparin, or vitamin K
                      antagonists).Median follow-up was 1.3 years. Compared with
                      patients without ATT, those receiving AC had significantly
                      improved 12-month progression-free survival (PFS; HR 0.55,
                      95 $\%$ CI 0.39-0.78, p = 0.001) and overall survival (OS;
                      HR 0.35, 95 $\%$ CI 0.19-0.64, p = 0.001). Direct oral
                      anticoagulants showed the most pronounced PFS benefit (HR
                      0.40, 95 $\%$ CI 0.25-0.64, p < 0.001). PAI was not
                      associated with a significant difference in PFS, but
                      multivariable Cox regression indicated a reduced hazard of
                      death (HR 0.48, 95 $\%$ CI 0.27-0.87, p = 0.015).Concomitant
                      AC, particularly factor Xa-inhibiting direct oral
                      anticoagulants, was associated with improved survival in
                      melanoma patients undergoing TT. These findings support
                      prospective trials evaluating AC as concomitant therapy in
                      advanced melanoma.},
      keywords     = {Anticoagulation (Other) / Melanoma (Other) / Targeted
                      therapy (Other)},
      cin          = {ED01 / A370},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331 / I:(DE-He78)A370-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41448065},
      doi          = {10.1016/j.ejca.2025.116195},
      url          = {https://inrepo02.dkfz.de/record/307460},
}